06.09.23 -- Have Questions About Your Small Molecule API And Drug Product Projects?

Our manufacturing capabilities span the requirements of Pfizer’s global small-molecule portfolio, and our open and collaborative approach means we can harness all of these resources. You can rely on us for high-quality API synthesis, from process development through long-term supply. Discover the difference with Pfizer CentreOne.

With world-class facilities, state-of-the-art equipment, and some of the industry’s most talented people, you can feel confident that your small molecule drug product is in safe hands. Learning from decades working with other small molecules, INCOG has been purpose-built to provide better solutions for the global injectable drug product sector.

The growing need for convenient and tamper-free packaging has proliferated the demand for blister packaging in the pharmaceutical industry. Ropack provides a number of contract blister packaging services and can produce blister packaging in several different forms, including regular thermo-form, cold-formed, and heat-sealed blister cards.

Societal specializes in modified-release formulations, including those for high potent and DEA controlled substances. No matter the scope of your project, we deliver — streamlining product formulation and manufacturing from concept to clinic to commercial scale.

As the biological activity and specificity of APIs increase, dosage strengths decrease, resulting in increased potency of the APIs in terms of occupational handling. PCI Pharma Services offers state-of-the-art containment equipment and a ‘Potent Passport’ philosophy to identify the specific handling requirements for any HPAPI project.

The popularity of modified-release (MR) dosage forms continues to rise due to the many therapeutic benefits that they offer for both drug developers and patients. Explore what therapeutic benefits oral MR dosages can offer and how Quotient Sciences can provide an end-to-end solution for the development of MR products.

With the industry’s focus on oncology and targeted therapies, the number of HPAPIs in development continues to increase, as does the demand for HPAPI manufacturing capacity. Lonza has more than 20 years’ experience in the manufacture and handling of HPAPIs and offers expertise, capabilities, manufacturing innovation, and integrated service options.

In the race to market, you need fast, cost-effective, and scientifically proven solutions to seamlessly guide your molecule through early-phase development. Discover Thermo Fisher's customized strategies and technical solutions that enable you to move your molecule through each early development phase with efficiency and speed.

We have 50 years of experience developing, manufacturing, and marketing oral and injectable-non-sterile APIs (NCEs and generics). In addition to our generics business, we currently offer a complete range of services — from API manufacturing to finished product formulation — by establishing alliances with strategic manufacturers and partners.

Learn how Syngene International's services — including chemical development, oligonucleotides, high potent API, performance and specialty materials, and ICH stability studies — can help you navigate the path from development to clinical trials and eventual commercialization.

We are your life science solutions partner who ensures you have the right end-to-end solutions to address challenges in early development, commercialization, and post-market for your combination products, biologics, pharmaceuticals, and medical devices.